A Top Takeover Target for 2016
– Bret Jensen, Editor, Biotech Gems
A top candidate for takeover consideration in 2016 started as a small bio pharmaceutical stock I alerted readers to at the beginning of this year.
It was one we were adding to replace another stock that had just been taken over buy a larger company to the tune of a 215% gain in less than 6 months… turning a $10,000 investment into $21,500 in a matter of months, not years. That company was Avanir Pharmaceuticals.
Our new company had some uncanny similarities to Avanir: small market capitalization, approved products, strong upward revenue trajectory, and a pristine balance sheet.
And possibly most importantly as I stated in my initial recommendation, “I also like the fact that insiders have not sold a single share of stock since coming public almost a year ago.”
These guys could have cashed out early on but they didn’t. They knew they had a good thing going and wanted to ride it on up.
And boy did they. By the time I told readers to started selling part of their initial positions this stock had given us a 464% return in just 5 months.
It’s a company I called “the company with backdoor access to skip the standard FDA approval process”.
Because of a strange loophole in the law for drug approval, this company can bypass the normal FDA process costing millions of dollars and taking years to complete with no guarantee of success.
Instead, this company gets drugs into the market, much, much quicker and for less cost than the bigger names.
Like Avanir, this company already had two products on the market — one drug to treat malignant hyperthermia and the other product was an anticoagulant compound.
But even more exciting was the deep pipeline of drugs it had in development, treating heat stroke, leukemia, lymphoma, and lung cancer.
If anyone of these treatments progressed, I knew the stock would take off.
And I didn’t have to wait long.
Just a little over a month after recommending the stock to my readers, the company tied up a lucrative deal with Teva Pharmaceuticals, a larger player, to license out the commercialization of the company’s leukemia and lymphoma treatment, Bendamustine.
These are the kinds of deals you need to find when investigating biotech firms. These are the game changers most everyone else misses.
This bumped the stock up by double figures — a sign of things to come.
Fast forward to June 2015, and my readers and I cashed out with a 464% gain, in under 6 months.
A true breakout stock.
And that’s without a buyout… yet.
In fact, this stock is still on my “buyout” watchlist, and while my readers have already taken a mammoth profit from it, I’ve advised them to keep a small amount in the stock to now “play with the House’s money” in the event the company continues to rise and goes on to book up to 1,400% gains like Medivation did just a few months prior.
I’d recommend you do the same too. No wild investment. Just a small amount that you may book a quick 30% – 100% on — or even more if the stock runs up higher!
That company is Eagle Pharmaceuticals. Its ticker is EGRX. Go ahead and write it down for now.
My new report, “3 Biotech Takeover Targets to Buy Now“, has more takeover candidates just like Avanir and Eagle… each with the potential for profits like the 1,400% from Medivation.
I’d like to send this report to you today, right now… a bit of solid stock research before the market opens tomorrow.
You’ll get this new report when you start a no-risk trial subscription to my newest investment advisory service, “Biotech Gems“.
Additionally, your risk-free trial of Biotech Gems gives you…
- You’ll this month’s issue, the December issue, and the January issue with no obligation to continue… It’s truly up to you: take the next 60 days, including the 3 monthly issues plus weekly updates, to decide if my research will bring you the massive gains you’ve been looking for.
- You’ll have access to my complete biotech portfolio… And access to my full research on every recommendation we’re holding. This portfolio is filled with many stocks similar to the ones I’ve shown you today.
- You’ll receive weekly updates… Stocks in the biotech sector move fast. You’ll always have the latest data on the biotech sector and guidance on our portfolio with weekly email updates from me.
- You’ll receive instant alerts from me… I’m invested in the same stocks you are, so I’m always monitoring our investments. Should sentiment sour on one of our investments, I’ll immediately let you know and advise you what to do to minimize the risk to your money. Likewise, should one of our investments take off, I’ll follow-up with instructions on how to lock in and maximize your profit even further.
- You’ll receive a monthly market briefing… Like any market, biotech has its ups and downs. Though in recent years, biotech has had way more ups and I expect that to continue! As part of your membership, I’ll keep you updated on what’s happening at a macro level and how that affects our investments.
- You’ll receive buy and sell instructions… Whenever I recommend a play, you’ll know exactly what to do to collect maximum profit. You’ll never be left in the dark wondering when to collect your returns, or whether you should add to your position.
- You’ll receive my personal email address… Should you ever have questions, comments or just want to say “hello” you’ll be able to contact me directly and receive a prompt reply! You can take comfort knowing that I’m only an email away if you ever need me.
- You’ll have 60 days to decide if you want to continue… That’s 3 full monthly issues, 13 weekly updates and any special supplements for you to enjoy and only then decide if you want to continue. If you don’t, then simply email or call for a full 100% refund of your $99.
- You’ll receive the new biotech report “3 Biotech Takeover Targets to Buy Now”. Plus if you act today you’ll get two bonus reports, “1 Stock Ready to Rocket on the Back of a “Sure Thing” Phase 3 Trial” and “1 Play, 3 Partnerships: The Stock with the Technology Big Pharma Wants”.
By this point you’re wondering how much it costs, right?
Well, the normal rate for Biotech Gems is $999 a year, still a bargain considering how much you’ll get.
Your rate won’t be anything near that. I’m extending the Black Friday special rate because I want to make it easy for you to say “yes”.
If you start a trial subscription today you can pick up Biotech Gems for just $99 a quarter. That comes out to just a little over a dollar a day… far less than even one morning coffee.
But this special pricing of $99 is only for today. So if you want to try Biotech Gems and not risk a thing for the next 60 days I urge you to sign up now.
Just click here to get started.
Happy Hunting.
Bret Jensen
Editor
Biotech Gems
P.S. This special sale rate won’t be available forever. In fact, it ends at 11:59 p.m. tonight. Lock in now and you’ll enjoy this month’s issue, next December’s issue, and the January issue and only then you decide if you want to continue profiting from biotech stocks or want to go on your way with a full 100% refund.